Synthesis and structure-activity relationship study of water-soluble carbazole sulfonamide derivatives as new anticancer agents

被引:43
作者
Liu, Yonghua [1 ]
Wu, Yanbin [1 ]
Sun, Lianqi [1 ]
Gu, Yuxi [1 ]
Hu, Laixing [1 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Inst Med Biotechnol, Beijing 100050, Peoples R China
基金
中国国家自然科学基金;
关键词
Water-soluble; Carbazole sulfonamide; Antitumor; In vivo; Structure-activity relationship; Pharmacokinetic parameters; INHIBITORS; ANTITUMOR; DISCOVERY; AVE8062; ANALOGS; DESIGN; LIGAND;
D O I
10.1016/j.ejmech.2020.112181
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Here, we formulated and investigated the structure-activity relationships of novel N-substituted carbazole sulfonamide derivatives with improved physicochemical properties. Most of these new compounds displayed good aqueous solubility. Certain molecules presented strong in vitro antiproliferative and in vivo antitumor activity. Relative to the control, 50 mg/kg compound 3v substantially reduced human HepG2 xenograft mouse tumor growth by 54.5% and its efficacy was comparable to that of CA-4P. Compound 3h demonstrated anticancer efficacy in both subcutaneous and orthotopic HepG2 xenograft mouse models. We also developed a novel synthetic method for 7-hydroxy-substituted carbazole sulfonamides. Compared with the control, 25 mg/kg compound 4c inhibited human HepG2 xenograft mouse tumor growth by 71.7% and was more potent than 50 mg/kg CA-4P with only 50% tumor shrinkage efficacy. Among the three water-soluble carbazole sulfonamide derivatives formulated in the present study, compound 4c displayed the most effective tumor growth inhibition in vivo and merit further investigation as potential antitumor agents for cancer therapy. (c) 2020 Elsevier Masson SAS. All rights reserved.
引用
收藏
页数:17
相关论文
共 27 条
  • [11] Combretastatins: In vitro structure-activity relationship, mode of action and current clinical status
    Jaroch, Karol
    Karolak, Maciej
    Gorski, Przemyslaw
    Jaroch, Alina
    Krajewski, Adrian
    Ilnicka, Aleksandra
    Sloderbach, Anna
    Stefanski, Tomasz
    Sobiak, Stanislaw
    [J]. PHARMACOLOGICAL REPORTS, 2016, 68 (06) : 1266 - 1275
  • [12] Tubulin Colchicine Binding Site Inhibitors as Vascular Disrupting Agents in Clinical Developments
    Ji, Ya-Ting
    Liu, Yan-Na
    Liu, Zhao-Peng
    [J]. CURRENT MEDICINAL CHEMISTRY, 2015, 22 (11) : 1348 - 1360
  • [13] Antitumor and antivascular effects of AVE8062 in ovarian carcinoma
    Kim, Tae Jin
    Ravoori, Murali
    Landen, Charles N.
    Kamat, Aparna A.
    Han, Liz Y.
    Lu, Chunhua
    Lin, Yvonne G.
    Merritt, William M.
    Jennings, Nicholas
    Spannuth, Whitney A.
    Langley, Robert
    Gershenson, David M.
    Coleman, Robert L.
    Kundra, Vikas
    Sood, Anil K.
    [J]. CANCER RESEARCH, 2007, 67 (19) : 9337 - 9345
  • [14] Synthesis of carbazole derivatives containing chalcone analogs as non-intercalative topoisomerase II catalytic inhibitors and apoptosis inducers
    Li, Peng-Hui
    Jiang, Hong
    Zhang, Wen-Jin
    Li, Yong-Lian
    Zhao, Min-Cong
    Zhou, Wei
    Zhang, Lan-Yue
    Tang, Ya-Dong
    Dong, Chang-Zhi
    Huang, Zhi-Shu
    Chen, Hui-Xiong
    Du, Zhi-Yun
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 145 : 498 - 510
  • [15] Tubulin inhibitors: a patent review
    Liu, Yi-Min
    Chen, Hsiao-Ling
    Lee, Hsueh-Yun
    Liou, Jing-Ping
    [J]. EXPERT OPINION ON THERAPEUTIC PATENTS, 2014, 24 (01) : 69 - 88
  • [16] Pharmacokinetics of the Rac/Cdc42 Inhibitor MBQ-167 in Mice by Supercritical Fluid Chromatography-Tandem Mass Spectrometry
    Maldonado, Maria del Mar
    Rosado-Gonzalez, Gabriela
    Bloom, Joseph
    Duconge, Jorge
    Ruiz-Calderon, Jean F.
    Hernandez-O'Farrill, Eliud
    Vlaar, Cornelis
    Rodriguez-Orengo, Jose F.
    Dharmawardhane, Suranganie
    [J]. ACS OMEGA, 2019, 4 (19): : 17981 - 17989
  • [17] The clinical development of new mitotic inhibitors that stabilize the microtubule
    Mani, S
    Macapinlac, M
    Goel, S
    Verdier-Pinard, D
    Fojo, T
    Rothenberg, M
    Colevas, D
    [J]. ANTI-CANCER DRUGS, 2004, 15 (06) : 553 - 558
  • [18] Anti-tubulin agents of natural origin: Targeting taxol, vinca, and colchicine binding domains
    Naaz, Fatima
    Haider, Md Rafi
    Shafi, Syed
    Yar, M. Shahar
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 171 : 310 - 331
  • [19] 1,1-Diheterocyclic Ethylenes Derived from Quinaldine and Carbazole as New Tubulin-Polymerization Inhibitors: Synthesis, Metabolism, and Biological Evaluation
    Naret, Timothee
    Khelifi, Ilhem
    Provot, Olivier
    Bignon, Jerome
    Levaique, Helene
    Dubois, Joelle
    Souce, Martin
    Kasselouri, Athena
    Deroussent, Alain
    Paci, Angelo
    Varela, Paloma F.
    Gigant, Benoit
    Alami, Mouad
    Hamze, Abdallah
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (04) : 1902 - 1916
  • [20] Novel carbazole sulfonamide microtubule-destabilizing agents exert potent antitumor activity against esophageal squamous cell carcinoma
    Niu, Fangfei
    Liu, Yonghua
    Jing, Zongpan
    Han, Gaijing
    Sun, Lianqi
    Yan, Lu
    Zhou, Lanping
    Wu, Yanbin
    Xu, Yang
    Hu, Laixing
    Zhao, Xiaohang
    [J]. CANCER LETTERS, 2018, 420 : 60 - 71